gdc

Newsworthy

Erleada First Drug Approved for Patients with Nonmetastatic Prostate Cancer
FDA Approvals, News & UpdatesNewsworthyProstate Cancer
On February 14, 2018, the FDA approved Erleada (apalutamide; from Janssen) for the treatment of patients with nonmetastatic, castration-resistant prostate cancer.
Verzenio Approved as Initial Treatment for Metastatic Breast Cancer
Breast CancerFDA Approvals, News & UpdatesNewsworthy
The CDK4/CDK6 inhibitor Verzenio received a new indication, for use alone or in combination with an aromatase inhibitor, as initial therapy in women with HR-positive, HER2-negative advanced or metastatic breast cancer.
Blincyto First Drug Approved for ALL and the MRD Biomarker
Cancer BiomarkersFDA Approvals, News & UpdatesLeukemiaNewsworthy
This is the first time the FDA has used minimal residual disease (MRD) as a biomarker to approve a specific treatment for patients with acute lymphoblastic leukemia (ALL).
FDA Approves First Direct-to-Consumer Genetic Test for 3 Types of BRCA Mutations in Men and Women
Cancer ScreeningFDA Approvals, News & UpdatesNewsworthy
This first-ever direct-to-consumer genetic test can provide information on potential risks to individuals who may not have access to genetic screening, but the information may be misleading without feedback from experts.
Quizartinib Significantly Improves Survival Over Chemotherapy in Patients with Relapsed/Refractory AML and FLT3-ITD Mutation
LeukemiaNewsworthyWeb Exclusives
This is the first treatment that targets patients with AML and the FLT3-ITD mutation. In this clinical trial, patients who received quizartinib lived longer without disease progression than those receiving chemotherapy.
Page 2 of 6
Results 11 - 20 of 55

Subscribe to CONQUER: the patient voice® magazine

Receive timely cancer news & updates, patient stories, and more.

Country